OsteoCure Therapeutics
Rebuilding the Aging Skeleton. Redefining Repair.
Team
Hunter Newman, PhD
Co-founder and CEO
Shyni Varghese, PhD
Co-founder and CTO
Ken Gall, PhD
Board Member
Kenneth Lyles, MD
Clinical Advisor
Technology
OsteoCure Therapeutics is a Duke University spinout developing first-in-class adenosine-based therapeutics to restore skeletal health. Our platform is designed to reverse bone loss, accelerate bone repair, and improve healing outcomes across osteoporosis, fracture healing, spinal fusion, and orthopedic surgery.
Backed by strong preclinical data in healthy and impaired healing models, OsteoCure is redefining how bone loss and bone repair are treated across a multibillion-dollar market.
Publications
In Vivo Sequestration of Innate Small Molecules to Promote Bone Healing
Bone patch containing bornic acid demonstrated biomaterial assisted sequestration of small molecules to localize pro-regenerative signaling at the injury site and accelerate bone repair.
Microgel-Assisted Delivery of Adenosine to Accelerate Fracture Healing
Application of the in situ curing scaffolds containing adenosine-loaded microgels following tibial fracture injury showed improved bone tissue healing in a mouse model.
Multi-Functional Small Molecule Alleviates Fracture Pain and Promotes Bone Healing
Demonstrates the dual role of adenosine and its material-assisted local delivery as a feasible therapeutic approach to treat bone trauma and associated pain.
Calcium Phosphate-Bearing Matrices Induce Osteogenic Differentiation of Stem Cells through adenosine signaling
Extracellular phosphate uptake through solute carrier SLC20a1 supports osteogenic differentiation of human mesenchymal stem cells via adenosine.
Extracellular adenosine signaling in bone health and disease
Purinergic signaling is a key molecular pathway in the maintenance of bone health and regeneration. P1 receptor signaling, which is activated by extracellular adenosine, has emerged as a key metabolic pathway that regulates bone tissue formation, function, and homeostasis
Small molecule–driven direct conversion of human pluripotent stem cells into functional osteoblasts
Direct conversion of hPSCs into functional osteoblasts through the use of adenosine. The hPSCs treated with adenosine not only expressed the molecular signatures of osteoblasts but also produced calcified bone matrix.
Address
701 W Main St Durham, NC 27701
Phone Number
973-600-1842
Mailing Address
hnewman@osteocuretx.com